Skip to main content
IMCCNasdaqinactive

IM Cannabis Corp.

·Vancouver, BC, Canada·CEO: Mr. Oren Shuster

IMCC evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for IMCC—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

Market Cap

$1.6M

Cash Runway

Lead Asset

Next Catalyst

Financial data as of Dec 31, 2025.

Run IM Cannabis Corp. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available IM Cannabis Corp. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

6

Total value held

$5K

Short Interest

as of Apr 21, 2026
% of float
1.1%
Days to cover
0.1
Shares short
60,258
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

IMCC short interest

Frequently asked questions

Who is the CEO of IM Cannabis Corp.?

Mr. Oren Shuster is the chief executive officer of IM Cannabis Corp. (IMCC).

Where is IM Cannabis Corp. headquartered?

IM Cannabis Corp. (IMCC) is headquartered in Vancouver, BC, Canada.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.